How Long Does Pneumovax 23 Last
Pneumovax 23 protection is generally considered to last at least five years in healthy adults, though immunity may wane faster in older adults or those with certain medical conditions. The CDC does not routinely recommend a second dose for most people who received their first dose at age 65 or older, but specific situations call for revaccination.
More from this site
Keep reading the latest coverage
Who Might Need a Second Dose
The CDC recommends a single revaccination with Pneumovax 23 for certain groups five or more years after their first dose. This includes people with chronic heart, lung, or liver disease, diabetes, alcohol dependence, or smokers. Individuals with functional or anatomic asplenia, or those with compromised immune systems from conditions like HIV or cancer, may also need a second dose depending on their initial vaccination timeline.
Effectiveness Over Time
Pneumovax 23 is a polysaccharide vaccine that protects against 23 strains of Streptococcus pneumoniae. Antibody levels decline over time, and real-world effectiveness against pneumococcal pneumonia drops more noticeably after several years compared with the initial protection. Studies show that protection against invasive pneumococcal disease tends to hold up better than protection against non-invasive pneumonia, though exact timelines vary by population.
Pneumovax 23 vs. PCV13 and PCV20
Newer pneumococcal conjugate vaccines, such as PCV13 and PCV20, may offer stronger and longer-lasting immune responses because they use a protein carrier. The CDC currently prioritizes PCV20 or PCV15 followed by Pneumovax 23 for adults who have not previously received a pneumococcal conjugate vaccine. People who already received Pneumovax 23 can still get a conjugate vaccine, but the timing depends on their age and vaccination history.
Key Takeaways
- Pneumovax 23 protection typically lasts at least five years.
- Revaccination is not routine for all adults but is recommended for high-risk groups after five years.
- Antibody levels decline with age, so protection may be shorter in older adults.
- Conjugate vaccines like PCV20 are now preferred for initial vaccination in many adults.